A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients by Claudia Cabrera et al.
RESEARCH ARTICLE Open Access
A retrospective, longitudinal study
estimating the association between
interdialytic weight gain and cardiovascular
events and death in hemodialysis patients
Claudia Cabrera1*, Steven M. Brunelli2, David Rosenbaum3, Emmanuel Anum2, Karthik Ramakrishnan2,
Donna E. Jensen2, Nils-Olov Stålhammar1 and Bergur V. Stefánsson1
Abstract
Background: Greater interdialytic weight gain (IDWG) is associated with risk of all-cause mortality and
hospitalization. Dialysis patients are also at greater risk of cardiovascular (CV) events than patients without kidney
disease. This retrospective study examined the potential association between IDWG and specific types of CV events.
Methods: Data were obtained from United States Renal Data System claims and the electronic health records of
Medicare patients who initiated hemodialysis between 01 January 2007 and 31 December 2008 at a large dialysis
organization. Absolute IDWG was defined as predialysis weight minus postdialysis weight from the prior treatment,
and relative IDWG was calculated as percentage of postdialysis weight with mean values for each, calculated over
dialysis days 91 to 180. Patient outcomes were considered beginning on day 181, continuing until death,
discontinuation of care, censoring, or study end (31 December 2009). Outcomes included all-cause mortality, CV
mortality, hospitalization for nonfatal heart failure/volume overload, hospitalization for nonfatal myocardial
infarction, MACE (a composite measure of nonfatal myocardial infarction, nonfatal ischemic stroke, or CV death),
and MACE+ (events comprising MACE as well as arrhythmia, nonfatal hemorrhagic stroke, or hospitalization for
heart failure). Associations between IDWG and outcomes over the exposure period were estimated using
proportional hazards regression and adjusted for baseline characteristics.
Results: 39,256 patients qualified for analysis. In general, associations of relative IDWG with outcomes were more
potent, consistent, and monotonic than those for absolute IDWG. Relative IDWG > 3.5 % body weight was
independently associated with all outcomes studied: point estimates ranged from 1.18 (myocardial infarction) to
1.26 (CV mortality) and were consistent among patients with and without diabetes, and with and without baseline
heart failure. Absolute IDWG > 3 kg was associated with outcomes other than myocardial infarction: point estimates
ranged from 1.11 (MACE) to 1.20 (heart failure).
Conclusions: Greater IDWG is associated with an increased risk of CV morbid events. Strategies that mitigate IDWG
may improve CV health and survival among hemodialysis patients.
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Background
Patients with end-stage renal disease (ESRD) represent an
important and increasingly prevalent portion of the
medical patient population. There were 615,899 persons
in the United States with ESRD in 2011, of which 430,273
were treated with dialysis [1], and the burden of concomi-
tant illness is high in this patient population. Among
ESRD patients treated with hemodialysis, the rate of
hospitalization is 1.84/patient-year, with nearly one-third
of these hospitalizations for cardiovascular (CV) causes
[2]. Mitigating the rate of negative CV outcomes in dialy-
sis patients has significant public health implications.
One plausible determination of poor CV outcomes in this
population is interdialytic weight gain (IDWG). By virtue of
implied limitations for renal excretion of endogenous salt
and water and intermittent treatment schedules, thrice-
weekly hemodialysis patients undergo repeated periods of
fluid retention. Clinically, accumulated fluid is measured as
IDWG (i.e., the change in weight from the end of one
treatment until the beginning of the next). It has been
demonstrated that greater IDWG is associated with a
greater risk of all-cause mortality [3–5]. However, to date,
there have been few studies directly examining the associ-
ation between IDWG and CV morbid events. CV events
are significant in their own right, occurring at a rate
of approximately 510 admissions/1000 patient-years in
hemodialysis patients and representing about 27 % of hos-
pitalizations in this population [2], and also may serve as
intermediary pathways linking IDWG to mortality.
This retrospective study examines the risk of CV
events experienced by patients with ESRD undergoing
hemodialysis. These analyses have been conducted to
estimate the independent associative risks that exist
between indices of interdialytic fluid accumulation and
dialytic fluid removal with clinical outcomes, particu-
larly, incident CV events and deaths. In addition, there
is no consensus as to whether IDWG is best considered
in absolute terms (i.e., kilograms of body weight change)
or in relative terms (i.e., body weight change expressed
as a proportion of body weight). To add clarity, we consid-
ered IDWG in both an absolute and relative manner and
examined the comparative associations with outcomes.
Methods
Retrospective data from patients in this study were ex-
tracted from the proprietary database of a large dialysis
organization (LDO) in the United States. Eligible pa-
tients were those who initiated in-center hemodialysis at
the LDO between 01 January 2007 and 31 December
2008 within 30 days of first dialysis. Because outcome
data were abstracted from Medicare claims, analytic
consideration was limited to patients with Medicare Part
A primary insurance.
Upon dialysis initiation, patients undergo a period of
adaptation during which target weight is identified, and
dialysis treatments and medications are titrated before
arriving at a quasi-steady state. To account for this, we did
not consider IDWG over dialysis days 1 to 90 (the “equili-
bration period”) but instead over the 90-day period span-
ning from dialysis days 91 to 180 (the “exposure period”).
Outcomes were considered beginning on dialysis day 181
and continuing until patients died, were censored for loss
to follow-up (transfer of care, transplant, modality change,
withdrawal from dialysis), or until 31 December 2009
(the “outcome period”). A schematic is provided in Fig. 1.
Implicitly, patients who did not survive on hemodialysis
Fig. 1 Study schema. Depicted are the time periods over which study data were considered. Abbreviations: IDWG, interdialytic weight gain
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until the start of the outcome period were excluded. This
study design and patient population have been described
previously [6].
Absolute IDWG was abstracted from patients’ electronic
health records and was defined as predialysis weight from
one treatment minus postdialysis weight from the prior
treatment, which represents fluid accumulation between
dialysis treatments (1 kg weight gain equals approximately
1 L fluid accumulated). Each patient’s mean IDWG value
was then calculated over the exposure period. Absolute
IDWG was considered as a continuous variable and also in
a dichotomous sense; for the latter, a threshold of 3.0 kg
was chosen based on empiric observations and prior litera-
ture [4]. Relative weight gain (relative IDWG) was calcu-
lated as a percentage of postdialysis weight. This measure
described the amount of fluid accumulated between dialysis
treatments as a function of the patient’s body size. Relative
IDWG was considered as a continuous variable and
also in a dichotomous sense; for the latter, a threshold
of 3.5 % was chosen based on empiric observations
and prior literature [7].
Covariates considered for the analysis included age, sex,
race, vascular access type, etiology of ESRD, and prior renal
transplant, as well as baseline history of diabetes, heart
failure, myocardial infarction, atrial fibrillation, cerebrovas-
cular disease (ischemic stroke, hemorrhagic stroke, or tran-
sient ischemic attack), and uncontrolled hypertension
(mean predialysis blood pressure > 140/90 mm Hg or mean
postdialysis blood pressure > 130/85 mm Hg during expos-
ure period). Covariate data were abstracted from patients’
electronic health records and comorbidity data were sup-
plemented from United States Renal Data System (USRDS)
form 2728 data. Demographics were considered as of the
start of the outcome period; comorbidities were considered
based on all data available as of the start of the outcome
period. IDWG and blood pressures, which were used to
define uncontrolled hypertension, were considered over the
exposure period.
The defined study outcomes were based on claims data
from the Medicare Institutional Claims and Claims Detail
Standard Analytical Files from the USRDS. The following
outcomes were studied: all-cause mortality, CV mortality
(defined as death attributed to myocardial infarction, ath-
erosclerotic heart disease, cardiac arrhythmia, congestive
heart failure, cardiomyopathy, cardiac arrest, valvular heart
disease, pulmonary edema, cerebrovascular accident inclu-
ding intracranial hemorrhage, or ischemic brain damage/
anoxic encephalopathy), hospitalization for nonfatal heart
failure/volume overload, hospitalization for nonfatal myo-
cardial infarction, and 2 composite endpoints for major
adverse CV events [MACE (nonfatal myocardial infarction,
nonfatal ischemic stroke, or CV death) and MACE+
(events comprising MACE as well as arrhythmia, nonfatal
hemorrhagic stroke, or hospitalization for heart failure)].
Analyses were performed in parallel for absolute and
relative IDWG. Baseline patient characteristics were de-
scribed as means, SDs, counts, and proportions and
compared across groups using t-tests and chi-squared
tests. Associations with outcomes were estimated using
Cox proportional hazards models. IDWG was considered
as a restricted cubic spline and unadjusted associations
with outcomes were estimated. Restricted cubic splines
allow for flexible examination of associative patterns, with
minimal assumptions regarding the shape of associations.
Unadjusted and adjusted associations were estimated for
dichotomous formulations of IDWG. The latter were
adjusted for covariates listed above. For absolute IDWG,
we fit additional models in which outcomes were also ad-
justed for body weight; relative IDWG was not adjusted
for body weight because, upon body weight adjustment
(i.e., when body weight is held analytically constant), rela-
tive IDWG is equivalent to absolute IDWG. Body weight
was used in preference to body mass index due to missing
height data. Finally, in considering CV mortality, we per-
formed a sensitivity analysis using a competing risks
model to account for the competing risk of non-CV mor-
tality [8].
This study was performed retrospectively from de-
identified electronic health records, and therefore deemed
exempt by an institutional review board (Quorom).
Results and discussion
Table 1 demonstrates baseline characteristics of the
39,256 patients qualifying for study. Overall, mean age
was 62.2 years; 43.9 % were female, 46.0 % of patients were
white, 31.7 % were black, and 14.7 % were Hispanic.
Etiology of ESRD was diabetes in 47.1 %, hypertension in
30.4 %, glomerular disease in 7.2 %, and some other cause
in 15.3 % of patients. At baseline, 68.2 % of patients had
diabetes, 39.8 % had a history of heart failure, and 25.3 %
had a history of myocardial infarction; 1.8 % of patients had
received prior transplants and were initiating hemodialysis
in the setting of a failed transplant. The distributions of
relative and absolute IDWG are shown in Fig. 2. Mean rela-
tive IDWG was 3.1 %; the distribution was noticeably right
skewed. Mean absolute IDWG was 2.4 kg; the distribution
was more symmetrical than relative IDWG distribution,
but still somewhat right skewed.
Incidence rates for events of interest during the out-
come period are provided in Table 2. Hospitalizations
for nonfatal myocardial infarction occurred at a rate
of 59.5 events/1000 patient-years, hospitalizations for
heart failure/volume overload at a rate of 243 events/
1000 patient-years, MACE at a rate of 108 events/1000
patient-years, MACE+ at a rate of 324 events/1000
patient-years, CV mortality at a rate of 55.8 deaths/1000
patient-years, and all-cause mortality at a rate of 142
deaths/1000 patient-years.
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Table 1 Baseline characteristics of the cohort overall and stratified on relative and absolute interdialytic weight gain
Variablea Overall N = 39,256 Relative IDWG Absolute IDWG
≤3.5 % n = 24,726 >3.5 % n = 14,530 p-value ≤3.0 kg n = 28,942 >3.0 kg n = 10,314 p-value
Age, year 62.2 ± 15.3 63.0 ± 15.0 60.7 ± 15.6 <0.001 63.7 ± (15.3 57.9 ± 14.2 <0.001
Female sex 17,238 (43.9) 11,462 (46.4) 5776 (39.8 %) <0.001 14,180 (49.0) 3058 (29.7) <0.001
Race <0.001 <0.001
White 18,055 (46.0) 11,975 (48.5) 6080 (41.9) 13,358 (46.2) 4697 (45.6)
Black 12,437 (31.7) 7951 (32.2) 4486 (30.9) 9008 (31.1) 3429 (33.3)
Hispanic 5777 (14.7) 3153 (12.8) 2624 (18.1) 4279 (14.8) 1498 (14.5)
Asian 1260 (3.2) 635 (2.6) 625 (4.3) 1044 (3.6) 216 (2.1)
Other 984 (2.5) 586 (2.4) 398 (2.7) 742 (2.6) 242 (2.4)
ESRD etiology <0.001 <0.001
Diabetes 18,500 (47.1) 11,068 (44.8) 7432 (51.2) 12,649 (43.7) 5851 (56.7)
Hypertension 11,942 (30.4) 7834 (31.7) 4108 (28.3) 9361 (32.3) 2581 (25.0)
Glomerular disease 2825 (7.2) 1927 (7.8) 898 (6.2) 2190 (7.6) 635 (6.2)
Other 5989 (15.3) 3897 (15.8) 2082 (14.4) 4742 (16.4) 1247 (12.1)
Prior renal txp 697 (1.8) 366 (1.5) 331 (2.3) <0.001 507 (1.8) 190 (1.8) 0.55
Baseline diabetesb 26,768 (68.2) 16,337 (66.1) 10,431 (71.8) <0.001 18,765 (64.8) 8003 (77.6) <0.001
Baseline CHFb 15,623 (39.8) 9340 (37.8) 6283 (43.2) <0.001 11,008 (38.0) 4615 (44.8) <0.001
Baseline MIb 9920 (25.3) 6238 (25.2) 3682 (25.3) 0.81 7274 (25.1) 2646 (25.7) 0.30
Baseline AFb 2310 (5.9) 1433 (5.8) 877 (6.0) 0.33 1720 (5.9) 590 (5.7) 0.41
Baseline CVDc 3404 (8.7) 2129 (8.6) 1275 (8.8) 0.58 2560 (8.9) 844 (8.2) 0.04
Uncontrolled hypertensiond 37,283 (95.0) 23,492 (95.0) 13,791 (94.9) 0.68 27,464 (94.9) 9819 (95.2) 0.22
Vascular access <0.001 <0.001
AVF 10,787 (27.7) 6826 (27.6) 4052 (27.9) 7728 (26.7) 3150 (30.6)
AVG 3782 (9.6) 2269 (9.2) 1513 (10.4) 2776 (9.6) 1006 (9.8)
CVC 24,573 (62.6) 15,616 (63.2) 8957 (61.7) 18,420 (63.7) 6153 (59.7)
Postdialysis weight, kg 77.0 (34.7) 80.3 (41.2) 71.4 (17.8) <0.001 73.3 (37.2) 87.4 (23.5) <0.001
Abbreviations: AF atrial fibrillation, CHF congestive heart failure, CVD cerebrovascular disease, AVF arteriovenous fistula, AVG arteriovenous graft, CVC central venous
catheter, ESRD end-stage renal disease, IDWG interdialytic weight gain, MI myocardial infarction, txp transplant
aValues expressed as mean ± SD or n (%)
bDefined based on CMS Medical Evidence Form 2728 data, claims (1 inpatient or 2 outpatient), or LDO EHR records prior to dialysis day 180
cDefined based on CMS Medical Evidence Form 2728, claims (1 inpatient or 2 outpatient), LDO EHR record prior to dialysis day 180. Includes ischemic stroke,
hemorrhagic stroke, and TIA
dDefined as mean predialysis blood pressure > 140/90 mm Hg or postdialysis blood pressure > 130/85 mm Hg during the outcome period (dialysis days 91–180)
Fig. 2 Distribution of interdialytic weight gain. Provided is the distribution of relative (panel a) and absolute IDWG (panel b) for the study cohort;
IDWG was considered over dialysis days 91–180 as described in the text. Abbreviation: IDWG, interdialytic weight gain
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Unadjusted associations of absolute and relative IDWG
with each outcome of interest are shown in Fig. 3. In
general, associations with an outcome were more potent
for relative versus absolute IDWG. For most outcomes,
associations with relative IDWG were relatively mono-
tonic, whereas the association with absolute IDWG was
less consistent and demonstrated threshold effects. For
myocardial infarction, a threshold effect was observed
with relative IDWG as well; nonetheless, the association
was more potent for relative versus absolute IDWG.
Considered dichotomously, compared to patients with
low relative and absolute IDWG, respectively, patients
with high relative (>3.5 %) and absolute IDWG (>3 kg),
respectively, were on average younger and less likely to
dialyze via a catheter, but were more likely to have
baseline diabetes or heart failure. These and other
comparisons are presented in Table 1. Associations were
synchronous except that high relative IDWG was associ-
ated with lower body weight whereas high absolute IDWG
was associated with higher body weight.
Table 3 presents unadjusted and adjusted associa-
tions between absolute and relative IDWG and end-
points during the outcome period. On an unadjusted
basis, higher relative IDWG was associated with greater
risk of each outcome studied. Upon multivariable adjust-
ment, estimates were slightly potentiated but qualitatively
similar. Measures of associations ranged from 14 %
greater risk (myocardial infarction) to 26 % greater risk
(CV mortality).
On an unadjusted basis, higher absolute IDWG was
associated with a greater risk of hospitalization for heart
failure/volume overload and MACE+, but not other out-
comes. Upon multivariable adjustment, estimates were
mildly potentiated; significant adjusted associations were
observed for all-cause mortality (7 % greater risk), heart
failure/volume overload (14 % greater risk), and MACE+
(14 % greater risk). Upon further adjustment for body
weight, greater absolute IDWG was associated with all
outcomes considered except for heart failure. Measures
of association ranged from 11 % (MACE) to 20 % (heart
failure/volume overload).
To determine whether risk of poor outcomes might be
modified by underlying diabetes or baseline heart failure,
we conducted restriction subgroup analyses (Fig. 4).
Results demonstrate that associations of high relative
IDWG with outcomes were similar in diabetic and non-
diabetic patients and in patients with and without base-
line heart failure.
Finally, a sensitivity analysis was conducted in which the
association between high relative IDWG and CV mortality
was analyzed under a competing risks framework. The
association was not meaningfully different from that
observed in the primary analysis: hazard ratio (95 % CI)
for relative IDWG> 3.5 % was 1.26 (1.20–1.33).
CV-related morbidity and mortality are greater in
ESRD patients compared to the general population [9].
This is probably related to the vast constellation of
underlying conditions that contribute to the deterior-
ation of the circulatory system, such as chronic hypervo-
lemia, high blood pressure, and periodic episodes of
intravascular hypovolemia with attendant tissue hypoxia,
all superimposed on a background of vascular disease,
diabetes, and autonomic nervous system dysfunction.
These data suggest that IDWG may contribute inde-
pendently and substantively to CV burden.
For the most part, dialysis patients are completely
reliant on the dialysis procedure for fluid removal. There
is sound biologic basis as to why greater IDWG may be
harmful. Acutely, greater volumes of retained fluid in-
crease cardiac filling pressures and predispose patients
to left ventricular strain, pulmonary edema, and exces-
sive blood pressure. In addition, because dialysis treat-
ment time is essentially fixed for most US patients,
greater IDWG implies a greater rate of fluid removal
during dialysis (i.e., ultrafiltration), which is associated
with hemodynamic instability and death [4, 10–14].
Table 2 Event count and incidence rates for outcomes of interest during the outcome period




Incidence rate to first event,
1000 patient-years (95 % CI)
MI 2378 40.0 386 (221, 588) 59.5 (57.1–61.9)
HF 8802 36.2 340 (184, 543) 243 (238–248)
MACEa 4314 40.1 387 (221, 589) 108 (105–111)
MACE+b 11,488 35.4 330 (174, 533) 324 (381–330)
CV mortalityc 2294 41.1 398 (232, 602) 55.8 (53.6–58.2)
All-cause mortality 5818 41.1 398 (232, 602) 142 (138–145)
Abbreviations: p25 twenty-fifth quartile, p50 fiftieth quartile, CI confidence interval, CV cardiovascular, HF heart failure/volume overload, MACE major adverse
cardiovascular event, MI myocardial infarction
aDefined as nonfatal myocardial infarction, nonfatal ischemic stroke, or CV death
bDefined as events comprising MACE as well as arrhythmia, nonfatal hemorrhagic stroke, or hospitalization for heart failure
cDefined as death attributed to MI, atherosclerotic heart disease, cardiac arrhythmia, congestive HF, cardiomyopathy, cardiac arrest, valvular heart disease,
pulmonary edema, or cerebrovascular accident including intracranial hemorrhage or ischemic brain damage/anoxic encephalopathy
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Fig. 3 (See legend on next page.)
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Chronic or repeated episodes of fluid retention contribute
to maladaptive changes in cardiac structure, such as left
ventricular hypertrophy and fibrosis, which may distort
electrical conduction pathways and promote ventricular
tachyarrhythmia and sudden cardiac death. Moreover,
data demonstrate that asymptomatic pulmonary conges-
tion and overhydration on bioimpedance are potently
associated with increased risk of death in otherwise stable
hemodialysis patients [15, 16]. Hur et al. found significant
improvements of left ventricular hypertrophy, blood pres-
sure, and pulse wave velocity targeting normohydration
amid the interdialytic period instead of the end of the dia-
lysis session with the help of bioimpedance, implying that
restricting fluid exposure reduces CV complications [17].
There are several plausible mechanisms behind the find-
ings, including stunning, strain of IDWG itself, or dry
weight that is greater than optimal, as these patients are
difficult to bring down to normohydration. Further, it is
possible that IDWG necessitates rapid ultrafiltration since
the duration of dialysis is fixed from a practical stand-
point. However, the distinction between these 2 circum-
stances is not possible with the current study design, but
shows only that minimizing IDWG is potentially import-
ant. Earlier studies have demonstrated that ESRD patients
experiencing large IDWG have an increased risk of death
compared to those with lesser weight gain between dialy-
sis sessions [4, 13].
The results presented here are consistent and extend
prior findings by demonstrating potent associations
between IDWG and CV morbid events and CV mortality
[3, 18]. In building upon these prior data, the present
findings are noteworthy because they provide a physio-
logic and clinical link between fluid accumulation and
mortality, demonstrate profound clinical and economic
implications, and imply that mitigating IDWG could
improve health and survival among ESRD patients. Unlike
past studies that considered only composite endpoints,
our robust sample size enabled us to assess associations
with individual outcomes of interest. Moreover, it afforded
greater statistical power to detect associations between
smaller increments in IDWG and outcomes than have
been previously reported.
There are 2 ways of expressing IDWG for clinical and
research purposes: absolute IDWG and relative IDWG,
the latter expressed as a percentage of body weight.
There is no clear consensus in the literature as to which
of these metrics is more clinically relevant. Our data in-
dicate that relative IDWG is more potently, consistently,
and monotonically associated with the outcomes studied
than is absolute IDWG, and therefore may be the more
relevant parameter. If so, this would suggest that small
patients may be particularly vulnerable to the effects of
high IDWG by virtue of having less ability to “store”
excess fluid between dialysis sessions. However,
(See figure on previous page.)
Fig. 3 Unadjusted associations of relative (panels a-f) and absolute (panels g-l) interdialytic weight gain with outcomes of interest. In each
analysis, IDWG was modeled as a restricted cubic spline. Displayed are point estimates (line) and 95 % CI (shaded areas). Abbreviations: CI,
confidence interval; CV, cardiovascular; HF, heart failure/volume overload; HR, hazard ratio; IDWG, interdialytic weight gain; MACE, major adverse
cardiovascular event; MI, myocardial infarction
Table 3 Adjusted and unadjusted associations between interdialytic weight gain and outcomes of interest
Relative IDWG Absolute IDWG
Outcomes Unadjusted
HR (95 % CI)
Adjustedd
HR (95 % CI)
Unadjusted
HR (95 % CI)
Adjustedd
HR (95 % CI)
Adjustedd + postdialysis
weight HR (95 % CI)
>3.5 % (vs ref≤ 3.5 %) >3.5 % (vs ref≤ 3.5 %) >3 kg (vs ref≤ 3 kg) >3 kg (vs ref≤ 3 kg) >3 kg (vs ref≤ 3 kg)
MI 1.14 (1.05–1.24) 1.18 (1.08–1.28) 0.94 (0.86–1.03) 1.02 (0.93–1.12) 1.07 (0.97–1.18)
HF 1.19 (1.14–1.24) 1.20 (1.15–1.26) 1.08 (1.03–1.13) 1.14 (1.09–1.20) 1.20 (1.14–1.26)
MACEa 1.19 (1.12–1.27) 1.21 (1.14–1.29) 0.98 (0.92–1.05) 1.04 (0.97–1.12) 1.11 (1.03–1.19)
MACE+b 1.18 (1.14–1.23) 1.22 (1.17–1.26) 1.05 (1.01–1.10) 1.14 (1.09–1.19) 1.19 (1.14–1.25)
CV mortalityc 1.23 (1.14–1.34) 1.23 (1.13–1.34) 1.00 (0.91–1.09) 1.04 (0.94–1.15) 1.12 (1.02–1.24)
All-cause mortality 1.22 (1.16–1.29) 1.26 (1.20–1.33) 0.97 (0.92–1.03) 1.07 (1.00–1.13) 1.17 (1.10–1.24)
Abbreviations: CI confidence interval, CV cardiovascular, MI myocardial infarction, HF heart failure/volume overload, HR hazard ratio, IDWG interdialytic weight gain,
MACE major adverse cardiovascular event, ref reference
aDefined as nonfatal myocardial infarction, nonfatal ischemic stroke, or CV death
bDefined as events comprising MACE as well as arrhythmia, nonfatal hemorrhagic stroke, or hospitalization for heart failure
cDefined as death attributed to MI, atherosclerotic heart disease, cardiac arrhythmia, congestive HF, cardiomyopathy, cardiac arrest, valvular heart disease,
pulmonary edema, or cerebrovascular accident including intracranial hemorrhage or ischemic brain damage/anoxic encephalopathy
dHRs were adjusted for age, race, sex, etiology of end-stage renal disease, prior renal transplant, access type, and baseline diabetes, uncontrolled hypertension, HF,
MI, atrial fibrillation, and ischemic/hemorrhagic stroke or transient ischemic attack
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inference in this regard should be undertaken cautiously.
High relative IDWG was associated with smaller body
size whereas high absolute IDWG was associated with
larger body size. Considering the known association be-
tween body size and clinical outcomes [19], this distinc-
tion could explain the discrepancies observed. Of note
in this regard is that the associations between absolute
IDWG and outcomes were potentiated upon adjustment
for body weight. Analogous adjustment for relative
IDWG could not be undertaken because—when body
weight is held analytically constant as in the case of
statistical adjustment—absolute and relative IDWG con-
verge to the same construct. Further research is needed
to elaborate the contributions of relative and absolute
IDWG, including dilutional studies demonstrating distri-
bution of accumulated fluid within relevant body com-
partments. Until such is known, the most conservative
interpretation of these findings would be to consider the
weight-adjusted outcomes for absolute IDWG: that
greater IDWG is associated with heart failure exacer-
bation, MACE, MACE+, CV mortality, and all-cause
mortality but not with myocardial infarction.
Study limitations include the retrospective design of
this analysis, which can lead to confounding. Specific to
this study, we lacked data on residual urine output. This
could potentially have confounded findings if, and to the
degree that, residual urine output impacts outcomes in-
dependently of effects mediated through IDWG. There
may have been residual confounding due to comorbid
conditions not considered, or the severity of those that
were. It is noteworthy that in the study by Lee et al.,
high relative IDWG was associated with an increased
risk of MACE, even after adjustment for urine produc-
tion and nutritional status [18]. Another confounding
factor to acknowledge is that patients may have been
nonadherent to dialysis, leading to larger IDWG
between sessions, thereby inflating the measurement of
IDWG. Again, this could confound findings to the degree
that poor dialysis attendance impacted outcomes inde-
pendent of intermediary effects on IDWG. The duration
of follow-up in this study was relatively short (potential
follow-up time ranged from 1–3 years based on the date
of accrual). However, normative data demonstrate that
median survival time for hemodialysis patients in the
Fig. 4 Adjusted associations of relative interdialytic weight gain with outcomes of interest in subgroups of patients with and without baseline
diabetes (panel a) and heart failure (panel b). HRs are shown with 95 % CIs. HRs were adjusted for age, race, sex, etiology of end-stage renal
disease, prior renal transplant, access type, and baseline diabetes, uncontrolled hypertension, HF, MI, atrial fibrillation, and ischemic/hemorrhagic
stroke or transient ischemic attack. Abbreviations: CI, confidence interval; CV, cardiovascular; HF, heart failure/volume overload; HR, hazard ratio;
MACE, major adverse cardiovascular event; MI, myocardial infarction
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United States is only 3 years, and thus our time horizon is
relevant [20].
Finally, of note this study considered IDWG. This is a
separate, though related concept to chronic fluid accumula-
tion (eg, as measured by bioimpedance, online hematocrit
monitoring, or soluble biomarkers) [21, 22]. Additional
studies are needed to better understand how cyclical fluid
changes represented by IDWG and chronic volume expan-
sion interact with respect to clinical outcomes.
Conclusions
In summary, the current analysis has demonstrated potent
and independent associations between greater IDWG and
risk of CV events, particularly hospitalization for heart
failure/volume overload and mortality. Observational re-
search and clinical trials are needed to evaluate if current
and upcoming strategies and therapies that mitigate
IDWG may improve CV health and survival among ESRD
patients.
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